China SFDA Encourages Regulatory Consultations In New Communication Guidelines
This article was originally published in PharmAsia News
Executive Summary
China hopes strengthened communication with sponsors will spur innovation and new drug approvals.
You may also be interested in...
China Drug Approvals Up 26%, Mostly Due To Generics
China's State FDA increased drug approvals by more than 26% in 2010, with the boost largely due to an increase in generic drug approvals. The agency also cleared more clinical trials for drugs that treat diseases that have a large societal impact, according to SFDA's second annual report on the status of drug approvals
BrightGene Bets On Remdesivir Amid Patent Questions
Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.
Stress Test: Coronavirus Challenges China Emergency Approval Mechanism
A regulatory pathway set up in China post-SARS is under stress test in the latest coronavirus outbreak, while emergency measures adopted by the country's regulator mean it’s much less burdensome to obtain approvals than before.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports